ChromaDex Corporation (CDXC): Price and Financial Metrics
CDXC Price/Volume Stats
| Current price | $1.52 | 52-week high | $1.99 |
| Prev. close | $1.54 | 52-week low | $1.25 |
| Day low | $1.46 | Volume | 36,300 |
| Day high | $1.55 | Avg. volume | 49,681 |
| 50-day MA | $1.44 | Dividend yield | N/A |
| 200-day MA | $1.48 | Market Cap | 114.19M |
CDXC Stock Price Chart Interactive Chart >
CDXC POWR Grades
- CDXC scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.79% of US stocks.
- The strongest trend for CDXC is in Growth, which has been heading down over the past 26 weeks.
- CDXC's current lowest rank is in the Momentum metric (where it is better than 27.6% of US stocks).
CDXC Stock Summary
- CHROMADEX CORP's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 82.32% of US listed stocks.
- The ratio of debt to operating expenses for CHROMADEX CORP is higher than it is for about just 11.79% of US stocks.
- Over the past twelve months, CDXC has reported earnings growth of -66.32%, putting it ahead of merely 19.91% of US stocks in our set.
- Stocks that are quantitatively similar to CDXC, based on their financial statements, market capitalization, and price volatility, are AMRN, PMD, NEO, PWFL, and MYO.
- Visit CDXC's SEC page to see the company's official filings. To visit the company's web site, go to www.chromadex.com.
CDXC Valuation Summary
- CDXC's price/sales ratio is 1.3; this is 69.05% lower than that of the median Healthcare stock.
- Over the past 178 months, CDXC's price/sales ratio has gone down 0.2.
Below are key valuation metrics over time for CDXC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CDXC | 2023-12-29 | 1.3 | 3.9 | -16.6 | -12.3 |
| CDXC | 2023-12-28 | 1.3 | 4.1 | -17.2 | -12.8 |
| CDXC | 2023-12-27 | 1.3 | 4.0 | -16.8 | -12.5 |
| CDXC | 2023-12-26 | 1.3 | 4.0 | -17.0 | -12.6 |
| CDXC | 2023-12-22 | 1.3 | 4.0 | -16.8 | -12.5 |
| CDXC | 2023-12-21 | 1.3 | 4.0 | -16.8 | -12.5 |
CDXC Growth Metrics
- The year over year net income to common stockholders growth rate now stands at -28.42%.
- Its 2 year revenue growth rate is now at 38.42%.
- Its year over year cash and equivalents growth rate is now at -53.03%.
The table below shows CDXC's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 68.813 | -19.714 | -20.447 |
| 2022-06-30 | 69.058 | -21.893 | -28.318 |
| 2022-03-31 | 70.025 | -25.956 | -27.487 |
| 2021-12-31 | 67.449 | -24.163 | -27.128 |
| 2021-09-30 | 65.135 | -19.197 | -27.9 |
| 2021-06-30 | 62.007 | -17.123 | -23.259 |
CDXC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CDXC has a Quality Grade of C, ranking ahead of 67.33% of graded US stocks.
- CDXC's asset turnover comes in at 1.115 -- ranking 18th of 682 Pharmaceutical Products stocks.
- MYGN, REPH, and ENDP are the stocks whose asset turnover ratios are most correlated with CDXC.
The table below shows CDXC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 1.115 | 0.615 | -3.082 |
| 2021-06-30 | 1.178 | 0.612 | -2.751 |
| 2021-03-31 | 1.276 | 0.607 | -3.100 |
| 2020-12-31 | 1.545 | 0.595 | -2.616 |
| 2020-09-30 | 1.466 | 0.586 | -2.883 |
| 2020-06-30 | 1.361 | 0.577 | -2.841 |
CDXC Price Target
For more insight on analysts targets of CDXC, see our CDXC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.80 | Average Broker Recommendation | 1.3 (Strong Buy) |
ChromaDex Corporation (CDXC) Company Bio
ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. The company is based inIrvine, California.
Latest CDXC News From Around the Web
Below are the latest news stories about CHROMADEX CORP that investors may wish to consider to help them evaluate CDXC as an investment opportunity.
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®LOS ANGELES, December 20, 2023--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce its inaugural initiative to support the US Military. |
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+Neurohacker Collective, an acclaimed American science team that has been formulating advanced nutritional supplements since 2015, has just created an NAD+ supplement called Qualia NAD+ that tackles the challenge of boosting NAD+ levels in aging Americans.* |
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)LOS ANGELES, November 30, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson’s disease (PD). This study was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented NR ingredient, Niagen®, the most efficient and high quality NAD+ precur |
An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% UndervaluedKey Insights The projected fair value for ChromaDex is US$2.57 based on 2 Stage Free Cash Flow to Equity ChromaDex is... |
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) PatientsLOS ANGELES, November 15, 2023--ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a phase II clinical study published in the peer-reviewed journal, Movement Disorders, by a team of researchers led by Dr. Hilde Nilsen, University of Oslo, Arkershus University Hospital, Norway. The clinical trial was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented nicot |
CDXC Price Returns
| 1-mo | 2.70% |
| 3-mo | 10.95% |
| 6-mo | -4.40% |
| 1-year | -16.48% |
| 3-year | -73.57% |
| 5-year | -56.32% |
| YTD | 6.29% |
| 2023 | -14.88% |
| 2022 | -55.08% |
| 2021 | -22.08% |
| 2020 | 11.37% |
| 2019 | 25.66% |
Continue Researching CDXC
Want to do more research on ChromaDex Corp's stock and its price? Try the links below:ChromaDex Corp (CDXC) Stock Price | Nasdaq
ChromaDex Corp (CDXC) Stock Quote, History and News - Yahoo Finance
ChromaDex Corp (CDXC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...